Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Revenue projections:

Revenue projections for GLENMARK
Revenue projections for GLENMARK

Revenues for Glenmark Pharmaceuticals Limited are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 1.77200
forwardPE 21.94759
debtToEquity 5.64600
earningsGrowth 65.75000
revenueGrowth 0.14300
grossMargins 0.72045
operatingMargins 0.16302
trailingEps 48.26000
forwardEps 97.96064

GLENMARK's current ratio 1.772, suggesting the company has sufficient liquidity to service its short-term debt. With its cash reserves and current assets in good shape, GLENMARK can comfortably meet its immediate liabilities, reflecting a healthy financial standing.
Glenmark Pharmaceuticals Limited's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
Positive earnings and revenue growth for GLENMARK suggest that the company is expected to grow its business. This trend reflects strong financial performance, with continued profitability and sales increases indicating a bright outlook for future expansion.
GLENMARK's forward EPS is higher than its trailing EPS, suggesting the company is expected to improve its profitability this financial year. This reflects growing confidence in GLENMARK's earnings potential, with forecasts indicating better financial performance than in the prior year.

Price projections:

Price projections for GLENMARK
Price projections for GLENMARK

GLENMARK's price projections have steadily risen over time, pointing to increasing optimism about the company's prospects. This upward revision suggests that analysts expect GLENMARK to continue delivering solid performance in the future.

Recommendation changes over time:

Recommendations trend for GLENMARK
Recommendations trend for GLENMARK


Analysts have shown a buy bias for GLENMARK, marking it as a favorable investment option. This could inspire investors to see GLENMARK as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.